Product Images Metoprolol Succinate

This is a medical document presenting the results of a study on the use of Wetoprolol Succinate in patients with heart failure. The results indicate that Wetoprolol Succinate helps to reduce total mortality and hospitalization due to heart failure. The document also presents the results for subgroups of patients based on various factors such as race, gender, and medical history. The study also shows the relative risk and confidence interval for myocardial infarction.*

Each tablet contains Metoprolol Succinate and Metoprolol Tarat in different amounts. The tablets are for oral use and come in extended-release form. The medication should be stored at a controlled room temperature and protected from moisture. It is important to keep the tablets out of reach of children. The pharmaceutical company, Oryza Pharmaceuticals, Inc. manufactured the tablets for RxOnly use. The description is not available for the illegible text.*

This is a description of medications containing Metoprolol Succinate and Metoprolol Tartrate. The dosage and usage details for Metoprolol Succinate are provided in the package insert, and the tablets should be stored at a controlled room temperature. The medication is manufactured by Oyia Pharmaceuticals in Coral Springs, FL and by Visum Pharmaceutical Co. in Halou, China. The text also contains a warning to keep all medications out of the reach of children.*

This is a medication description for Metoprolol Succinate Extended-Release Tablets manufactured by Oryza Pharmaceuticals. Each tablet contains 180 mg of metoprolol succinate equivalent to 200 mg of metoprolol artate. The dosage and usage instructions are provided in the package insert. It should be stored at a controlled room temperature of 25°C (77°F), between 15°C to 30°C (59°F-86°F), and protected from moisture. The warning advises against keeping the medication accessible to children. The NDC code is 72516-033-01.*